Michelle Renee Griffin Adaptive Biotechnologies Corp (ADPT) insider trading activity

Michelle Renee Griffin is Director of Adaptive Biotechnologies Corp. Currently has a direct ownership of 51,955 shares of ADPT, which is worth approximately $243,668. The most recent transaction as insider was on Mar 04, 2024, when has been sold 31,328 shares (Common Stock) at a price of $0.0 per share, resulting in proceeds of $0. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 52K

0% 3M change

151.88% 12M change

Total Value Held $243,668

MICHELLE RENEE GRIFFIN Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Mar 04 2024	BUY Grant, award, or other acquisition	-	31,328 Added 37.62%	51,955 Common Stock
Mar 27 2023	SELL Open market or private sale	$19,875 $8.49 p/Share	2,341 Reduced 10.19%	20,627 Common Stock
Mar 06 2023	BUY Grant, award, or other acquisition	-	14,775 Added 39.15%	22,968 Common Stock
Jan 26 2022	BUY Grant, award, or other acquisition	-	6,689 Added 44.95%	8,193 Common Stock
Aug 27 2021	SELL Open market or private sale	$522,060 $35.0 p/Share	14,916 Reduced 90.84%	1,504 Common Stock
Aug 27 2021	BUY Exercise of conversion of derivative security	$116,345 $7.8 p/Share	14,916 Added 47.6%	16,420 Common Stock
Jul 14 2021	SELL Open market or private sale	$92,000 $36.8 p/Share	2,500 Reduced 62.44%	1,504 Common Stock
Jul 14 2021	BUY Exercise of conversion of derivative security	$19,500 $7.8 p/Share	2,500 Added 38.44%	4,004 Common Stock
Jun 17 2021	SELL Open market or private sale	$160,000 $40.0 p/Share	4,000 Reduced 72.67%	1,504 Common Stock
Jun 17 2021	BUY Exercise of conversion of derivative security	$31,200 $7.8 p/Share	4,000 Added 42.09%	5,504 Common Stock
Jun 14 2021	SELL Open market or private sale	$96,400 $38.56 p/Share	2,500 Reduced 62.44%	1,504 Common Stock
Jun 14 2021	BUY Exercise of conversion of derivative security	$19,500 $7.8 p/Share	2,500 Added 38.44%	4,004 Common Stock
May 18 2021	SELL Open market or private sale	$87,500 $35.0 p/Share	2,500 Reduced 62.44%	1,504 Common Stock
May 18 2021	BUY Exercise of conversion of derivative security	$19,500 $7.8 p/Share	2,500 Added 38.44%	4,004 Common Stock
Apr 14 2021	SELL Open market or private sale	$195,345 $43.41 p/Share	4,500 Reduced 74.95%	1,504 Common Stock
Apr 14 2021	BUY Exercise of conversion of derivative security	$35,100 $7.8 p/Share	4,500 Added 42.84%	6,004 Common Stock
Mar 16 2021	SELL Open market or private sale	$70,500 $47.0 p/Share	1,500 Reduced 49.93%	1,504 Common Stock
Mar 16 2021	BUY Exercise of conversion of derivative security	$11,700 $7.8 p/Share	1,500 Added 33.3%	3,004 Common Stock
Mar 15 2021	SELL Open market or private sale	$186,885 $41.53 p/Share	4,500 Reduced 74.95%	1,504 Common Stock
Mar 15 2021	BUY Exercise of conversion of derivative security	$35,100 $7.8 p/Share	4,500 Added 42.84%	6,004 Common Stock
Feb 16 2021	SELL Open market or private sale	$390,480 $65.08 p/Share	6,000 Reduced 79.96%	1,504 Common Stock
Feb 16 2021	BUY Exercise of conversion of derivative security	$46,800 $7.8 p/Share	6,000 Added 44.43%	7,504 Common Stock
Feb 14 2021	BUY Grant, award, or other acquisition	-	1,504 Added 50.0%	1,504 Common Stock
Jan 14 2021	SELL Open market or private sale	$396,600 $66.1 p/Share	6,000 Reduced 100.0%	0 Common Stock
Jan 14 2021	BUY Exercise of conversion of derivative security	$46,800 $7.8 p/Share	6,000 Added 50.0%	6,000 Common Stock

Also insider at

KDNY

CHINOOK THERAPEUTICS, INC. Healthcare

Director

ACER

Acer Therapeutics Inc. Healthcare

Director

HTGM

HTG MOLECULAR DIAGNOSTICS, INC Healthcare

Director

MRG